This is a randomized, double-blinded, placebo-controlled phase 2b clinical trial to characterize, examine and compare the effects of GLP-1 receptor agonist (semaglutide) in HIV-infected adult individuals with lipohypertrophy versus healthy controls with obesity but without HIV.
The two populations will be studied in separate but similarly-designed studies running in parallel.
Subjects in both populations will be assigned by chance (1:1) to semaglutide or placebo.
NNC0174-0833 is a long acting medication that has been studied for management of diabetes. These trials showed a weight loss effect, so it is being studied here as a possible means of weight management treatment. The study seeks to determine the dose of NNC0174-0833, a long acting medication, which may be most effective for weight management for people suffering from overweight or obesity. This study is over a period of 26 weeks along with a 7-week follow-up period. Five doses of NNC0174-0833 will be compared against the drug liraglutide 3.0 mg and an inactive placebo.
Participants will be randomly assigned to receive one of these drugs. All participants will receive diet and physical activity counseling. Participants will inject themselves once-weekly or once-daily with study medication. The primary measure of the study will be weight change, body measurement, blood sugar measurement and safety and tolerability of the drug.
TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.